Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations.
Aleksandra Franovic(Ondine Biopharma (United States)), Eric S. Martin(Dana-Farber Cancer Institute), Adithi Mohan(Ondine Biopharma (United States)), Noelito Timple(Ondine Biopharma (United States)), Nichol Miller(Pfizer (United States)), Ping Jiang(Shanghai Jiao Tong University), Paul Severson(Ondine Biopharma (United States)), John Tyhonas(Ondine Biopharma (United States)), Sean Uryu(Pfizer (United States)), Nabeel Bardeesy(Broad Institute), Qibiao Wu(Macau University of Science and Technology), Eric A. Murphy(University of California San Diego), Robert S. Kania(RG Biopharma (United States))
Cited by 8
Related Papers
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
|Cell|2012|2k
Telomere dysfunction induces metabolic and mitochondrial compromise
|Nature|2011|1.3k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924